Heron Therapeutics, Inc. (HRTX) Stock Analysis

Heron Therapeutics to Report Second Quarter 2026 Financial Results on Monday, August 10, 2026

Mon, July 27, 2026 at 12:30 PM UTC 2 min read

Heron Therapeutics (HRTX) announced it will report its second quarter 2026 financial results on August 10, 2026. This update is significant for investors as it will provide insights into the company's financial health and progress on its product pipeline, potentially influencing stock performance and investor sentiment. Monitoring these results will be crucial for assessing Heron's market position and future growth prospects.

Read full article →

Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?

Tue, May 19, 2026 at 11:08 AM UTC 2 min read

Heron Therapeutics, Inc. (HRTX) saw its price target reduced to $4 by H.C. Wainwright, reflecting concerns over the company's revenue outlook and ongoing challenges in its product pipeline. This downgrade may signal to investors a more cautious approach towards Heron's growth potential and profitability, potentially impacting market sentiment and stock performance. Investors should closely monitor any developments in Heron's clinical trials and strategic initiatives moving forward.

Read full article →